NervGen Pharma (NGEN) AI Stock Analysis

• Market Cap: C$409.91M
• Dividend Yield: N/A
• Average Volume (3M): 93.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: N/A
• EPS Growth: 2.22%
• Country: CA
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 79,593,760
• 10 Day Avg. Volume: 180,731
• 30 Day Avg. Volume: 93,835
• PEG Ratio: 1.67
• Price to Book (P/B): 82.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$6.75
• Price Target Upside: 18.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: C$6.00 ▲(5.26% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

Score is held back primarily by weak financial performance (pre-revenue, widening losses, heavy cash burn, and negative equity). Offsetting factors include strong technical momentum (price above major moving averages with positive MACD) and constructive corporate catalysts (clinical/regulatory progress and new financing), while valuation remains constrained by lack of profitability and no dividend support.

Positive Factors

Low leverage

Very low recorded debt (roughly $33K TTM) materially reduces near-term creditor pressure and bankruptcy risk. For a cash-burning biotech, minimal leverage preserves optionality with lenders and allows management to prioritize equity or strategic financings over costly debt, a durable balance-sheet advantage.

Focused clinical pipeline (NVG-291)

A concentrated R&D program centered on NVG-291 focuses resources on a single differentiated nerve-regeneration candidate. This focused platform can accelerate decision cycles, align trial design and regulatory engagement, and if clinical success occurs, deliver high upside from a clear addressable therapeutic niche.

Regulatory/data catalysts and financing flexibility

Recent CONNECT SCI data, active FDA pathway discussions and a $10M private placement plus a Form F-10 filing represent structural progress: supportive clinical/regulatory engagement and explicit financing runway improve ability to continue development and pursue U.S. listing or follow-on raises under a regulated framework.

Negative Factors

Heavy cash burn

Sustained negative operating and free cash flow (~-$16.8M TTM) creates an enduring need for outside capital. This structural cash consumption increases dilution risk, pressures management to secure financing on market-dependent terms, and can constrain long-term program continuity if capital markets tighten.

Pre-revenue with widening losses

Zero revenue and widening net losses (around -$25.8M TTM) limit internal funding sources and lengthen the path to self-sufficiency. For a clinical-stage biotech, persistent increasing losses reduce margin of safety and raise dependency on successful trials or partnerships to materially alter the company's financial trajectory.

Negative equity and shrinking assets

Material deterioration to negative shareholder equity and a drop in total assets (from ~$23.9M to ~$13.1M) weaken the balance sheet's capacity to absorb shocks. This structural deterioration can raise financing costs, limit strategic options, and increase the likelihood of dilutive raises or asset sales to fund operations.

NervGen Pharma Business Overview & Revenue Model

Company Description

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

How the Company Makes Money

NervGen Pharma makes money primarily through the development and commercialization of its proprietary therapies. The company seeks to generate revenue by obtaining regulatory approvals for its drugs and then marketing these treatments to healthcare providers and patients. Key revenue streams include potential sales of approved drugs, licensing agreements with pharmaceutical companies, and milestone payments associated with collaborative partnerships. Additionally, NervGen may engage in research and development collaborations that provide funding to support its clinical trials and product development efforts.

NervGen Pharma Financial Statement Overview

Summary

Development-stage profile with zero revenue, widening net losses (about -$25.8M TTM) and heavy, worsening cash burn (FCF about -$16.8M TTM). Low debt is a positive, but negative equity (about -$2.9M TTM) and declining assets reduce financial flexibility and increase reliance on external funding.

Income Statement

The company remains pre-revenue (revenue is 0 across all periods), with persistent and sizable operating losses. Losses have not stabilized: net loss widened from about -$11.2M (2020) to -$24.0M (2024) and is about -$25.8M in TTM (Trailing-Twelve-Months), indicating a higher cost base and ongoing investment without offsetting commercial revenue. A modest positive is that results are broadly consistent with a development-stage biotech profile, but near-term profitability visibility is limited based on the data provided.

Balance Sheet

Leverage is low (total debt is minimal in all periods, including about $33K in TTM (Trailing-Twelve-Months)), which reduces financial risk from creditors. However, equity has deteriorated materially and is negative in TTM (Trailing-Twelve-Months) (about -$2.9M), a clear balance-sheet weakness that can constrain financing flexibility and reflects cumulative losses. Total assets have also declined versus earlier years (roughly $13.1M in TTM vs. ~$23.9M in 2022), suggesting reduced balance-sheet capacity over time even though debt remains small.

Cash Flow

Cash burn is heavy and persistent: operating cash flow and free cash flow are both negative each year, at about -$16.8M in TTM (Trailing-Twelve-Months). Cash outflow also worsened versus 2023 (free cash flow fell from about -$11.4M in 2023 to about -$16.8M in 2024/TTM), highlighting increased funding needs. One constructive point is that cash flow tracks net losses fairly closely (free cash flow is roughly in line with net income), but the overall profile still indicates ongoing external capital reliance.

Breakdown	TTM	Mar 2025	Mar 2024	Dec 2022	Dec 2021	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-41.85K	-83.80K	-145.00K	-115.11K	-42.63K	-39.65K
EBITDA	-25.42M	-23.92M	-17.63M	-20.09M	-12.77M	-11.16M
Net Income	-25.82M	-24.01M	-22.38M	-18.11M	-12.64M	-11.18M
Balance Sheet
Total Assets	13.08M	19.49M	13.24M	23.88M	17.90M	6.68M
Cash, Cash Equivalents and Short-Term Investments	11.40M	17.36M	11.66M	22.45M	16.93M	5.60M
Total Debt	33.23K	105.60K	197.19K	283.45K	0.00	0.00
Total Liabilities	16.02M	16.91M	15.25M	10.41M	1.08M	755.07K
Stockholders Equity	-2.94M	2.58M	-2.01M	13.46M	16.82M	5.92M
Cash Flow
Free Cash Flow	-16.76M	-16.84M	-11.44M	-17.81M	-8.31M	-6.31M
Operating Cash Flow	-16.76M	-16.84M	-11.30M	-17.78M	-8.27M	-6.31M
Investing Cash Flow	100.93K	58.87K	-138.85K	-21.11K	-45.09K	-3.42K
Financing Cash Flow	7.33M	22.70M	766.28K	22.64M	19.61M	7.85M

NervGen Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NGEN, the sentiment is Negative. The current price of 5.7 is above the 20-day moving average (MA) of 5.55, below the 50-day MA of 6.19, and above the 200-day MA of 4.61, indicating a neutral trend. The MACD of -0.21 indicates Positive momentum. The RSI at 40.57 is Neutral, neither overbought nor oversold. The STOCH value of 15.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NGEN.

NervGen Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NGEN	53 Neutral	C$409.91M	-14.39	-9999.00%	―	―	2.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRUG	44 Neutral	C$1.01B	-28.32	-30.79%	―	―	-43.64%
AGN	42 Neutral	C$1.86M	-1.17	―	―	―	64.77%

NervGen Pharma Corporate Events

NervGen Pharma Lists on Nasdaq to Support Late-Stage Push for Spinal Cord Injury Drug

NervGen Pharma began trading today on the Nasdaq under the symbol NGEN, a step the company expects will increase its visibility, trading liquidity and access to a broader and more diversified shareholder base as it advances its neuroreparative drug pipeline. The U.S. listing follows expanded Phase 1b/2a data from its CONNECT SCI study showing unprecedented, durable functional and quality-of-life improvements in chronic spinal cord injury patients treated with lead candidate NVG-291, and comes as NervGen prepares for an End-of-Phase 2 meeting with the FDA in early 2026 to define a registration pathway and moves toward late-stage development that could potentially reshape treatment options for spinal cord injury and related neurologic conditions.

The most recent analyst rating on (TSE:NGEN) stock is a Hold with a C$7.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.

NervGen Pharma Files SEC Registration to Advance Strategic Growth

NervGen Pharma has filed a Form F-10 registration statement with the U.S. Securities and Exchange Commission under the Multijurisdictional Disclosure System, allowing it to potentially accelerate its growth and strategic initiatives. This development not only reflects NervGen’s operational progress but also positions the company to strengthen its presence in the biopharmaceutical industry as it continues to advance clinical trials for groundbreaking therapies.

The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$7.70 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.

NervGen Pharma Proposes Amendment to Warrant Terms

NervGen Pharma announced its intention to amend the exercise price of 5,075,000 common share purchase warrants issued in 2022, changing it from US$1.75 to C$2.44 to align with the company’s functional currency. This amendment is aimed at simplifying accounting processes and is pending acceptance by the TSX Venture Exchange, reflecting NervGen’s ongoing efforts to streamline its financial operations.

The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$7.70 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.

NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment

NervGen Pharma has reported significant advancements in its CONNECT SCI Study, showcasing NVG-291’s potential to improve function, independence, and quality of life for individuals with chronic spinal cord injuries. The company has also completed a $10 million private placement to support a Nasdaq listing and received confirmation from the FDA on multiple regulatory routes for NVG-291’s approval, highlighting its promising therapeutic potential and reinforcing its industry positioning.

The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.

NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment

NervGen Pharma announced expanded data from its CONNECT SCI Study, showcasing unprecedented improvements in function, independence, and quality of life for individuals with chronic spinal cord injury. The study highlights NVG-291’s potential as the first pharmacologic treatment for spinal cord injury, with significant functional gains and quality of life improvements observed in participants, marking a significant milestone for the company and offering hope for the SCI community.

The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.

NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development

NervGen Pharma has successfully closed a US$10 million non-brokered private placement to support its anticipated Nasdaq listing and advance the development of its NVG-291 clinical program. The financing, which involved participation from institutional and accredited investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation, will help NervGen strengthen its market position and potentially enhance shareholder value. The transaction also involved related party participation, requiring compliance with specific securities regulations.

The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.

NervGen Pharma Secures $10 Million to Propel Nasdaq Listing and NVG-291 Development

NervGen Pharma has announced a US$10 million non-brokered private placement to support its anticipated Nasdaq listing and advance the development of NVG-291. This financing involves participation from both new and existing investors, including SCI Ventures, and reflects confidence in NervGen’s clinical progress. The proceeds will be used to further NVG-291’s clinical development and for general corporate purposes, marking a pivotal chapter in the company’s evolution into a late-stage biotech firm.

The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.